Participants with alcohol use disorder will be randomly assigned to either the Ria Treatment Platform or a waitlist control. The Ria Treatment Platform is a telehealth approach that incorporates medical assessment, medications for alcohol use disorder, individual and group coaching, educational video modules, and a Bluetooth-enabled breathalyzer. Patients are followed for three months during which data are collected, including measures of alcohol consumption and its consequences.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
135
combined medication, coaching, education, and monitoring
Stanford University
Stanford, California, United States
Percent of subjects without heavy drinking days
Heavy drinking is defined as 5 or more standard drinks per day for men and 4 or more standard drinks per day for women, as assessed by the Timeline Followback.
Time frame: Final 4 weeks of the 12-week trial period
Proportion of abstinent days
Any drinking as assessed by the Timeline Followback
Time frame: 12-week trial period
Liver function (ALT, AST, GGT)
Measures of liver function.
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.